Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × INDUSTRY × gancotamab × Clear all

Phase

Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Cisplatin 24 pembrolizumab 23 Gemcitabine 23 Carboplatin 23 Paclitaxel 20 Pemetrexed 13 Docetaxel 13 Drug Therapy 12 Capecitabine 12 Oxaliplatin 11 Bevacizumab 10 Nivolumab 9 Fluorouracil 9 130-nm albumin-bound paclitaxel 8 anlotinib 6 Trastuzumab 6 Temozolomide 5 atezolizumab 4 Rituximab 4 Leucovorin 4 Lenalidomide 4 Ipilimumab 4 Injections 4 Folfox protocol 4 venetoclax 3 pertuzumab 3 osimertinib 3 daratumumab 3 camrelizumab 3 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02213744 2017-01-06

HERMIONE

Merrimack Pharmaceuticals

Phase 2/3 Terminated

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡